Rankings
▼
Calendar
TKNO
Alpha Teknova, Inc.
$133M
Q4 2023 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$8M
-0.3% YoY
Gross Profit
$1M
17.0% margin
Operating Income
-$11M
-138.0% margin
Net Income
-$11M
-135.5% margin
EPS (Diluted)
$-0.26
QoQ Revenue Growth
-3.7%
Cash Flow
Operating Cash Flow
-$3M
Free Cash Flow
-$3M
Stock-Based Comp.
$1M
Balance Sheet
Total Assets
$129M
Total Liabilities
$39M
Stockholders' Equity
$90M
Cash & Equivalents
$28M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$8M
$8M
-0.3%
Gross Profit
$1M
$2M
-36.7%
Operating Income
-$11M
-$14M
+23.7%
Net Income
-$11M
-$13M
+19.8%
Revenue Segments
Lab Essentials
$7M
85%
Clinical Solutions
$879,000
11%
Other Product
$300,000
4%
Geographic Segments
UNITED STATES
$7M
94%
Non-US
$495,000
6%
← FY 2023
All Quarters
Q1 2024 →
TKNO Q4 2023 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena